{"id":"lacosamide-rapid-titration-2","safety":{"commonSideEffects":[{"rate":"25–38%","effect":"Dizziness"},{"rate":"10–13%","effect":"Headache"},{"rate":"8–17%","effect":"Nausea"},{"rate":"6–11%","effect":"Diplopia"},{"rate":"5–9%","effect":"Ataxia"},{"rate":"4–8%","effect":"Vomiting"},{"rate":"4–6%","effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lacosamide is a functionalized amino acid that selectively enhances slow inactivation of voltage-gated sodium channels, which reduces repetitive neuronal firing and prevents seizure propagation. This mechanism differs from traditional sodium channel blockers by preferentially affecting the slow inactivation phase rather than fast inactivation. The drug also has activity at collapsin response mediator protein 2 (CRMP-2), which may contribute to its anticonvulsant effects.","oneSentence":"Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:26.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Diabetic neuropathic pain"}]},"trialDetails":[{"nctId":"NCT00350103","phase":"PHASE3","title":"A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-06-30","conditions":"Painful Diabetic Neuropathy","enrollment":551},{"nctId":"NCT03607851","phase":"PHASE4","title":"Efficacy and Safety of Rapid Titration Protocols of Lacosamide","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-08-03","conditions":"Focal Epilepsy","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lacosamide - rapid titration 2","genericName":"Lacosamide - rapid titration 2","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity. Used for Partial-onset seizures (adjunctive therapy), Diabetic neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}